The US Preventive Services Task Force (USPSTF) has backtracked on low-dose aspirin for the prevention of colorectal cancer (CRC), stating in new guidance that the evidence is too murky to make a recommendation either for or against it.
The group dialed back from its 2016 recommendation because new findings from a handful of trials mean that the evidence is now “unclear whether aspirin use reduces the risk of CRC cancer incidence or mortality.”